In summary, our findings, obtained from both BRAF-mutated and P53-mutated melanoma cell lines, suggest that two reverse transcriptase inhibitors belonging to the NRTI and NNRTI classes, along with a new-generation integrase inhibitor, impact HERV-K gene expression as well as the growth and invasion capabilities of melanoma cells. This evidence concerns the gene BRAF and melanoma.